Research graph
References from Treatment outcomes after initiating buprenorphine/naloxone or methadone for opioid use disorder among First Nation Peoples in Ontario, Canada. Local targets link to admitted publications; unresolved targets remain external evidence.
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: A mixed methods systematic review
10.1186/s13011-023-00564-9 · 2023 · External reference
Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection
10.1371/journal.pone.0021748 · 2011 · External reference
Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research
10.1080/03610910902859574 · 2009 · External reference
An introduction to propensity score methods for reducing the effects of confounding in observational studies
10.1080/00273171.2011.568786 · 2011 · External reference
The opioid crisis in Canada: A national perspective
10.24095/hpcdp.38.6.02 · 2018 · External reference
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement
10.1371/journal.pmed.1001885 · 2015 · External reference
The intergenerational effects of Indian Residential Schools: Implications for the concept of historical trauma
10.1177/1363461513503380 · 2014 · External reference
Unresolved reference
2021 · External reference
Management of opioid use disorders: A national clinical practice guideline
10.1503/cmaj.170958 · 2018 · External reference
Social and economic characteristics of those experiencing hospitalizations due to opioid poisonings
2018 · External reference
Unresolved reference
2021 · External reference
Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence
10.1159/000520185 · 2022 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2025 · External reference
The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis
10.1097/yco.0000000000000717 · 2021 · External reference
Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies
10.1016/s2215-0366(23)00095-0 · 2023 · External reference
Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone
10.1503/cmaj.090784 · 2009 · External reference
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)
10.1111/j.1360-0443.2004.00654.x · 2004 · External reference
Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in Ontario: A population-based retrospective cohort study
10.1097/cxa.0000000000000192 · 2023 · External reference
The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
10.1111/add.15115 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
2023 · External reference
Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis
10.1016/j.drugalcdep.2022.109459 · 2022 · External reference
Charlson Comorbidity Index: ICD-9 update and ICD-10 translation
2019 · External reference
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: A population-based propensity-score matched cohort study
10.1111/add.15862 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
Retention in opioid agonist therapy among first nations people
10.1001/jamanetworkopen.2025.18452 · 2025 · External reference
Consolidated criteria for strengthening reporting of health research involving indigenous peoples: The CONSIDER statement
10.1186/s12874-019-0815-8 · 2019 · External reference
Deficit-based indigenous health research and the stereotyping of indigenous peoples
10.7202/1065690ar · 2019 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2026 · External reference
Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: Evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program
2015 · External reference
Duration of methadone and buprenorphine-naloxone treatment
10.1001/jamanetworkopen.2025.18389 · 2025 · External reference
Identifying diabetes cases from administrative data: A population-based validation study
10.1186/s12913-018-3148-0 · 2018 · External reference
Community-led recovery from the opioid crisis through culturally-based programs and community-based data governance
10.18584/iipj.2022.13.2.13792 · 2022 · External reference
Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study
2017 · External reference
Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: Protocol for a population-based target trial emulation
10.1136/bmjopen-2024-098318 · 2025 · External reference
Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder
10.1001/jama.2024.16954 · 2024 · External reference
Confronting racism within the Canadian healthcare system: Systemic exclusion of first nations from quality and consistent care
2020 · External reference
Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: An integrative review
10.1186/s13011-022-00463-5 · 2022 · External reference
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
10.1097/01.mlr.0000182534.19832.83 · 2005 · External reference
What impact did the COVID-19 pandemic have on the variability of fentanyl concentrations in the Vancouver, Canada illicit drug supply? An interrupted time-series analysis
2023 · External reference
Unmasking population undercounts, health inequities, and health service access barriers across Indigenous populations in urban Ontario
10.17269/s41997-024-00957-8 · 2024 · External reference
Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies
2017 · External reference
Unresolved reference
2025 · External reference
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission
10.1016/j.jsat.2020.108031 · 2020 · External reference
Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: A retrospective cohort study of US veterans
10.1007/s11606-021-06969-1 · 2022 · External reference
Unlocking First Nations health information through data linkage
10.23889/ijpds.v3i1.450 · 2018 · External reference
Harnessing the healing power of the land: Culturally appropriate treatments for Indigenous persons with a substance use disorder
10.3389/fpsyt.2026.1796719 · 2026 · External reference
Management of opioid use disorder: 2024 update to the national clinical practice guideline
10.1503/cmaj.241173 · 2024 · External reference
An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada
10.1016/j.dialog.2024.100190 · 2024 · External reference
Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder
10.1001/jama.2024.16954 · ExternalCitation · doi-reference
Duration of methadone and buprenorphine-naloxone treatment
10.1001/jamanetworkopen.2025.18389 · ExternalCitation · doi-reference
Retention in opioid agonist therapy among first nations people
10.1001/jamanetworkopen.2025.18452 · ExternalCitation · doi-reference
Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: A retrospective cohort study of US veterans
10.1007/s11606-021-06969-1 · ExternalCitation · doi-reference
An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada
10.1016/j.dialog.2024.100190 · ExternalCitation · doi-reference
Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis
10.1016/j.drugalcdep.2022.109459 · ExternalCitation · doi-reference
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission
10.1016/j.jsat.2020.108031 · ExternalCitation · doi-reference
Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies
10.1016/s2215-0366(23)00095-0 · ExternalCitation · doi-reference
An introduction to propensity score methods for reducing the effects of confounding in observational studies
10.1080/00273171.2011.568786 · ExternalCitation · doi-reference
Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research
10.1080/03610910902859574 · ExternalCitation · doi-reference
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
10.1097/01.mlr.0000182534.19832.83 · ExternalCitation · doi-reference
Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in Ontario: A population-based retrospective cohort study
10.1097/cxa.0000000000000192 · ExternalCitation · doi-reference
The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis
10.1097/yco.0000000000000717 · ExternalCitation · doi-reference
The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
10.1111/add.15115 · ExternalCitation · doi-reference
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: A population-based propensity-score matched cohort study
10.1111/add.15862 · ExternalCitation · doi-reference
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)
10.1111/j.1360-0443.2004.00654.x · ExternalCitation · doi-reference
Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: Protocol for a population-based target trial emulation
10.1136/bmjopen-2024-098318 · ExternalCitation · doi-reference
Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence
10.1159/000520185 · ExternalCitation · doi-reference
The intergenerational effects of Indian Residential Schools: Implications for the concept of historical trauma
10.1177/1363461513503380 · ExternalCitation · doi-reference
Consolidated criteria for strengthening reporting of health research involving indigenous peoples: The CONSIDER statement
10.1186/s12874-019-0815-8 · ExternalCitation · doi-reference
Identifying diabetes cases from administrative data: A population-based validation study
10.1186/s12913-018-3148-0 · ExternalCitation · doi-reference
Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: An integrative review
10.1186/s13011-022-00463-5 · ExternalCitation · doi-reference
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: A mixed methods systematic review
10.1186/s13011-023-00564-9 · ExternalCitation · doi-reference
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement
10.1371/journal.pmed.1001885 · ExternalCitation · doi-reference
Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection
10.1371/journal.pone.0021748 · ExternalCitation · doi-reference
Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone
10.1503/cmaj.090784 · ExternalCitation · doi-reference
Management of opioid use disorders: A national clinical practice guideline
10.1503/cmaj.170958 · ExternalCitation · doi-reference
Management of opioid use disorder: 2024 update to the national clinical practice guideline
10.1503/cmaj.241173 · ExternalCitation · doi-reference
Unmasking population undercounts, health inequities, and health service access barriers across Indigenous populations in urban Ontario
10.17269/s41997-024-00957-8 · ExternalCitation · doi-reference
Community-led recovery from the opioid crisis through culturally-based programs and community-based data governance
10.18584/iipj.2022.13.2.13792 · ExternalCitation · doi-reference
Unlocking First Nations health information through data linkage
10.23889/ijpds.v3i1.450 · ExternalCitation · doi-reference
The opioid crisis in Canada: A national perspective
10.24095/hpcdp.38.6.02 · ExternalCitation · doi-reference
Harnessing the healing power of the land: Culturally appropriate treatments for Indigenous persons with a substance use disorder
10.3389/fpsyt.2026.1796719 · ExternalCitation · doi-reference
Deficit-based indigenous health research and the stereotyping of indigenous peoples
10.7202/1065690ar · ExternalCitation · doi-reference
